Publication:
Efficacy and tolerability of 20% aluminum sesquichlorohydrate vs 20% aluminum chloride for the treatment of axillary hyperhidrosis: A randomized controlled trial

dc.contributor.authorThianboonsong T.
dc.contributor.authorKanokrungsee S.
dc.contributor.authorPaichitrojjana A.
dc.contributor.authorUdompataikul M.
dc.contributor.authorKamanamool N.
dc.contributor.authorRojhirunsakool S.
dc.date.accessioned2021-04-05T03:05:24Z
dc.date.available2021-04-05T03:05:24Z
dc.date.issued2020
dc.date.issuedBE2563
dc.description.abstractThis study evaluated the efficacy and tolerability of topical aluminum sesquichlorohydrate (AS) when compared to aluminum chloride (AC) as a treatment for primary axillary hyperhidrosis (PAH). Twenty subjects were included in this randomized, controlled, split-side 8-week study. All participants applied 20% AS and 20% AC lotions in their axillae (one treatment per axilla) every night for 2 weeks; next, the application was reduced to three times a week for 4 weeks. The assessment was performed using the sweating intensity visual scale (SIVS), hyperhidrosis disease severity score (HDSS), patient satisfaction score, and the appearance of adverse effects on weeks 0, 1, 2, 4, 6, and 8. Both AS as well as AC application showed positive results, significantly differing from the baseline, as assessed using SIVS, HDSS, and patient satisfaction score at every follow-up visit; however, no significant difference was observed between the AS and AC groups at any follow-up visit. The mean time of response was 1.14 weeks for both treatments. A side effect was observed in one subject (5%), who reported itching on the AC axilla. The therapeutic effects persisted even after reducing the frequency of application and lasted for at least 2 weeks after cessation of use. In conclusion, topical 20% AS demonstrated similar efficacy to topical 20% AC in the treatment of PAH, with a high safety profile. © 2020 Wiley Periodicals LLC.
dc.format.mimetypeapplication/pdf
dc.identifier.citationDermatologic Therapy. Vol 33, No.6 (2020)
dc.identifier.doi10.1111/dth.14354
dc.identifier.issn13960296
dc.identifier.other2-s2.0-85092284609
dc.identifier.urihttps://hdl.handle.net/20.500.14740/5817
dc.rightsSrinakharinwirot University
dc.rights.holderScopus
dc.subject.otherAluminum chloride
dc.subject.otherAluminum salt
dc.subject.otherAluminum sesquichlorohydrate
dc.subject.otherAntiperspirant agent
dc.subject.otherNon prescription drug
dc.subject.otherUnclassified drug
dc.subject.otherAdult
dc.subject.otherArticle
dc.subject.otherAxilla
dc.subject.otherClinical article
dc.subject.otherClinical evaluation
dc.subject.otherClinical observation
dc.subject.otherComparative effectiveness
dc.subject.otherControlled study
dc.subject.otherDisease severity assessment
dc.subject.otherDouble blind procedure
dc.subject.otherDrug efficacy
dc.subject.otherDrug safety
dc.subject.otherDrug tolerability
dc.subject.otherFemale
dc.subject.otherFollow up
dc.subject.otherHuman
dc.subject.otherHyperhidrosis
dc.subject.otherHyperhidrosis disease severity score
dc.subject.otherLotion
dc.subject.otherLow level laser therapy
dc.subject.otherMale
dc.subject.otherNight
dc.subject.otherPatient satisfaction
dc.subject.otherProspective study
dc.subject.otherPruritus
dc.subject.otherRandomized controlled trial
dc.subject.otherSkin disease assessment
dc.subject.otherSweating intensity visual scale
dc.subject.otherTherapy effect
dc.subject.otherTopical treatment
dc.subject.otherTreatment response
dc.titleEfficacy and tolerability of 20% aluminum sesquichlorohydrate vs 20% aluminum chloride for the treatment of axillary hyperhidrosis: A randomized controlled trial
dc.typeArticle
dspace.entity.typePublication
swu.datasource.scopushttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85092284609&doi=10.1111%2fdth.14354&partnerID=40&md5=a28dcd44bf2325cb63658e0cc502d497

Files